Impact of early initiation versus national standard of care of antiretroviral therapy in Swaziland's public sector health system: Study protocol for a stepped-wedge randomized trial

Trials

Volumn 18, Issue 1, 2017, Pages

  Walsh, Fiona J ^a   Bärnighausen, Till ^b,c,d   Delva, Wim ^e,f,g,h   Fleming, Yvette ⁱ   Khumalo, Gavin ^j   Lejeune, Charlotte L ^a   Mazibuko, Sikhathele ^k   Mlambo, Charmaine Khudzie ^a   Reis, Ria ^l,m,n   Spiegelman, Donna ^b   Zwane, Mandisa ^o   Okello, Velephi ^k  

^a CLINTON HEALTH ACCESS INITIATIVE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c AFRICA HEALTH RESEARCH INSTITUTE   (South Africa)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e STELLENBOSCH UNIVERSITY   (South Africa)

^f HASSELT UNIVERSITY   (Belgium)

^g GHENT UNIVERSITY   (Belgium)

^h REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

ⁱ AIDS Fonds   (Netherlands)

^j Swaziland National Network of People Living with HIV and AIDS   (Swaziland)

^k Ministry of Health   (Swaziland)

^l UNIVERSITY OF AMSTERDAM   (Netherlands)

^m LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ UNIVERSITY OF CAPE TOWN   (South Africa)

^o SAfAIDS   (Zimbabwe)

more..

Author keywords

Antiretroviral treatment; HIV AIDS; Prevention; Swaziland

Indexed keywords

ADULT; ANTIRETROVIRAL THERAPY; ARTICLE; CLINICAL OUTCOME; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DRUG RESISTANCE; EARLY INTERVENTION; ECONOMIC EVALUATION; FEASIBILITY STUDY; FEMALE; HEALTH CARE; HEALTH CARE COST; HEALTH CARE FACILITY; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PREDICTIVE VALUE; PUBLIC SECTOR; RANDOMIZED CONTROLLED TRIAL; SOCIOLOGY; SWAZILAND; TRANSITIONAL CARE; TREATMENT DURATION; TUBERCULOSIS; ANTIVIRAL RESISTANCE; CLINICAL PROTOCOL; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION; ECONOMICS; MEDICATION COMPLIANCE; METHODOLOGY; MICROBIOLOGY; MULTICENTER STUDY; OPPORTUNISTIC INFECTION; QUESTIONNAIRE; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ANTIRETROVIRUS AGENT;

ANTI-RETROVIRAL AGENTS; CLINICAL PROTOCOLS; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; EARLY MEDICAL INTERVENTION; FEASIBILITY STUDIES; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; OPPORTUNISTIC INFECTIONS; PATIENT SATISFACTION; PUBLIC SECTOR; RESEARCH DESIGN; SURVEYS AND QUESTIONNAIRES; SWAZILAND; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS; VIRAL LOAD;

EID: 85027693581     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-017-2128-8     Document Type: Article

References (27)

1. UNAIDS. Report on the Global HIV/AIDS Epidemic. Geneva: UNAIDS; 2000. http://data.unaids.org/pub/Report/2000/2000_gr_en.pdf. Accessed 17 July 2016.
2. UNAIDS. Global AIDS Update. Geneva: UNAIDS; 2016. http://www.unaids.org/en/resources/documents/2016/Global-AIDS-update. Accessed 17 July 2016.
3. UNAIDS. Fast-track update on investments needed in the AIDS response (2016). Geneva: UNAIDS. http://www.unaids.org/en/resources/documents/2016/unaids_fast-track_update_investments_needed. Accessed 1 Apr 2016.
4. Government of South Africa. Minister Aaron Motsoaledi: Health Department Budget Vote 2016/2017. 2016. http://www.gov.za/speeches/debate-health-budget-vote-national-assembly-10-may-2016-dr-aaron-motsoaledi-minister-health. Accessed 17 July 2016.
5. Atun R, Chang AY, Ogbuoji O, Silva S, Resch S, Hontelez J, et al. Long-term financing needs for HIV control in sub-Saharan Africa in 2015-2050: a modelling study. BMJ Open. 2016;6:e009656. doi: 10.1136/bmjopen-2015-009656.
6. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.
7. Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795-807. doi: 10.1056/NEJMoa1506816.
8. World Health Organization. Consolidated guidelines on the use of antiretroviral therapy for treating and preventing HIV infection: guidelines for a public health approach. Geneva: WHO; 2015.
9. Iwuji CC, Orne-Gliemann J, Tanser F, Boyer S, Lessells RJ, Lert F, et al. Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster randomized controlled trial. Trials. 2013;14:1-15. doi: 10.1186/1745-6215-14-230.
10. Iwuji C, Orne-Gliemann J, Balestre E, Larmarange J, Thiebaut R, Tanser F, et al. Abstract: The impact of universal test and treat on HIV incidence in a rural South African population: ANRS 12249 TasP trial, 2012-2016. In: International AIDS Conference 2016, Durban, South Africa. Durban; 2016. http://programme.aids2016.org/Abstract/Abstract/10537.
11. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection Recommendations for a public health approach. 2nd ed. Geneva: WHO; 2016.
12. Kingdom of Swaziland. Ministry of Health. National comprehensive HIV package of care for adults and adolescents in Swaziland. 2010. http://www.infocenter.nercha.org.sz/sites/default/files/Swaziland%20Integrated%20HIV%20Management%20Guidelines_0.pdf. Accessed 17 July 2016.
13. Bicego GT, Nkambule R, Peterson I, Reed J, Donnell D, Ginindza H, et al. Recent patterns in population-based HIV prevalence in Swaziland. PLoS One. 2013;8:e77101.
14. Kingdom of Swaziland. Ministry of Health. Annual HIV Programs Report 2015.
15. Hussey MA, Hughes JP. Design and analysis of stepped wedge cluster randomized trials. Contemp Clin Trials. 2007;28:182-91.
16. Hayes R, Ayles H, Beyers N, Sabapathy K, Floyd S, Shanaube K, et al. HPTN 071 (PopART): rationale and design of a cluster-randomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment - a study protocol for a cluster randomised trial. Trials. 2014;15:57.
17. BCCP: Botswana Combination Prevention Project. clinicaltrials.gov. 2015. https://clinicaltrials.gov/ct2/show/NCT01965470. Accessed 1 Sept 2016.
18. SEARCH: Sustainable East Africa Research in Community Health. clinicaltrials.gov. 2015. https://clinicaltrials.gov/ct2/show/NCT01864603?term=search+uganda&rank=1. Accessed 1 Sept 2016.
19. Orne-Gliemann J, Larmarange J, Boyer S, Iwuji C, McGrath N, Bärnighausen T, et al. Addressing social issues in a universal HIV test and treat intervention trial (ANRS 12249 TasP) in South Africa: methods for appraisal. BMC Public Health. 2015;15:209. doi: 10.1186/s12889-015-1344-y.
20. Liesenborgs J, Meng F, Hens N DW. Simpact Cyan 0.19. http://www.simpact.org/how-simpact-works/2016. Accessed 5 Aug 2016.
21. Delva W, Leventhal GE, Helleringer S. Connecting the dots: network data and models in HIV epidemiology. AIDS. 2016;30:2009-20.
22. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11:561-70.
23. Rotnitzky A, Robins JM. Semiparametric regression estimation in the presence of dependent censoring. Biometrika. 1995;82:805-20.
24. Fitzmaurice GM, Laird NM, Ware JH. Applied longitudinal analysis. XX: Wiley, New Jersey. 2004.
25. Little RJ, D'Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med. 2012;367:1355-60. doi: 10.1056/NEJMsr1203730.
26. Campbell MK, Piaggio G, Elbourne DR, Altman DG. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345(1):e5661. doi: 10.1136/bmj.e5661.
27. Hemming K, Haines TP, Chilton PJ, Girling AJ, Lilford RJ. The stepped wedge cluster randomised trial: rationale, design, analysis, and reporting. BMJ. 2015;350:h391.